Pfizer's COVID-19 pill, which includes HIV treatment, reduces the risk of hospitalization or death by 89%

Pfizer announced that its COVID-19 pill reduces the risk of hospitalization or death by up to 89% in high-risk adults exposed to the virus.

It is an antiviral drug developed after Merck's molnupiravir.

Pfizer stated that it plans to submit the data to the FDA "as soon as possible."

It's going to be a game-changer.

​In an interview with CNBC, Pfizer CEO Albert Bourla said the company plans to submit data to the FDA before Thanksgiving.

​Pfizer stated that it has "a production capacity of 500 million pills currently," which corresponds to 50 million treatments. "The extremely high efficacy has surprised us and exceeds our most forward-looking expectations."

Summary
The new COVID-19 treatment drug developed by Pfizer, Paxlovid

It is said that the effectiveness was so excellent that the clinical trials had to be terminated early.

​The new drug is said to reduce the probability of severe COVID-19 patients being hospitalized or dying by 89%.

Pfizer's new drug was announced to be more effective than Merck's molnupiravir, which was developed prior to this.

Pfizer's president said it is expected to be available to Americans within this year.

​Source: https://www.bbc.com/news/health-59178291

These are English translations of articles from our GTTOUR Japanese website.